Anti-drug Antibodies Inhibit Neutralization of TNF-alpha in Infliximab Treated Patients with Inflammatory Bowel Disease (IBD)

被引：0
|
作者：
Eser, A. [1 ]
Vogelsang, H. [1 ]
Reinisch, S. [2 ]
Novacek, G. [1 ]
Dejaco, C. [1 ]
Kazemi-Shirazi, L. [1 ]
Primas, C. [1 ]
Lichtenberger, C. [1 ]
Brehovsky, S. [1 ]
Singh, S. [3 ]
Jain, A. [3 ]
Reinisch, W. [2 ]
机构：
[1] Med Univ Vienna, Dept Gastroenterol & Hepatol, Vienna, Austria
[2] McMaster Univ, Dept Internal Med, Hamilton, ON, Canada
[3] Prometheus Labs, Dept Res & Dev, San Diego, CA USA
来源：
JOURNAL OF CROHNS & COLITIS | 2015年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P449
引用
收藏
页码：S304 / S305
页数：2
相关论文
共 50 条
  • [1] The temporal evolution of anti-drug antibodies in IBD patients treated with infliximab
    Ben-Horin, Shomron
    Ungar, Bella
    Chowers, Yehuda
    Yavzori, Miri
    Picard, Orit
    Fudim, Ella
    Eliakim, Rami
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 145 - 145
  • [2] INDUCTION ANTI-TNF DRUG LEVELS AND ANTIBODIES AT WEEK 6 IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS TREATED WITH INFLIXIMAB
    Garcia, Karoline S.
    Queiroz, Natalia S.
    Parra, Rogerio S.
    Feres, Omar
    Chebli, Julio
    Chebli, Liliana A.
    Flores, Cristina
    Vieira, Andrea
    Azevedo, Matheus
    Carlos, Alexandre S.
    Oba, Jane
    Alves, Olivia D.
    Ceara, Christianne D.
    Sipahi, Aytan M.
    Damiao, Aderson O.
    [J]. GASTROENTEROLOGY, 2022, 162 (07) : S1097 - S1097
  • [3] Importance of Determining Anti-drug Antibodies in the Treatment of inflammatory Bowel Disease with Infliximab
    Langmann, Anna
    Langmann, Peter
    [J]. INTERNIST, 2019, 60 : S8 - S8
  • [4] Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease
    Strik, A. S.
    van den Brink, G. R.
    Ponsioen, C.
    Mathot, R.
    Loewenberg, M.
    D'Haens, G. R.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 45 (08) : 1128 - 1134
  • [5] ANTI-DRUG ANTIBODIES (ADA): ASSAY PERFORMANCE IN PATIENTS TREATED FOR INFLAMMATORY BOWEL AND RHEUMATIC DISEASE WITH BIODRUGS, ADALIMUMAB AND INFLIXIMAB
    O'Donnell, J.
    Liu, J.
    Keating, P.
    Hock, B.
    Spellerberg, M.
    Barclay, M.
    Stamp, L.
    [J]. INTERNAL MEDICINE JOURNAL, 2017, 47 : 15 - 15
  • [6] Anti-Drug Antibodies in Patients with Inflammatory Bowel Diseases Treated with Biosimilar Infliximab: A Prospective Cohort Study
    Pekala, Anna
    Filip, Rafal
    Aebisher, David
    [J]. JOURNAL OF CLINICAL MEDICINE, 2021, 10 (12)
  • [7] The optimal management of anti-drug antibodies to infliximab and identification of anti-drug antibody values for clinical outcomes in patients with inflammatory bowel disease
    Neasa Mc Gettigan
    Aman Shah Afridi
    Grace Harkin
    Caroline Lardner
    Stephen Patchett
    Danny Cheriyan
    Gavin Harewood
    Karen Boland
    Aoibhlinn O’Toole
    [J]. International Journal of Colorectal Disease, 2021, 36 : 1231 - 1241
  • [8] The optimal management of anti-drug antibodies to infliximab and identification of anti-drug antibody values for clinical outcomes in patients with inflammatory bowel disease
    Mc Gettigan, Neasa
    Afridi, Aman Shah
    Harkin, Grace
    Lardner, Caroline
    Patchett, Stephen
    Cheriyan, Danny
    Harewood, Gavin
    Boland, Karen
    O'Toole, Aoibhlinn
    [J]. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2021, 36 (06) : 1231 - 1241
  • [9] Disappearance of anti-drug antibodies to infliximab and adalimumab after addition of an immunomodulator in patients with inflammatory bowel disease
    Strik, A.
    van den Brink, G.
    Ponsioen, C.
    Mathot, R.
    Lowenberg, M.
    D'Haens, G.
    [J]. JOURNAL OF CROHNS & COLITIS, 2016, 10 : S69 - S70
  • [10] MONITORING OF TNF-ALPHA BLOCKERS INFLIXIMAB AND ADALIMUMAB BY MEASURING TROUGH LEVEL CONCENTRATIONS AND ANTI-DRUG ANTIBODIES
    Westerlund, Johanna
    Jokiranta, T. Sakari
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2012, 41 (04) : 325 - 325
12345